(Career Enhancement Program) The goal of the Career Enhancement Program (CEP) is to provide training and guidance for academic physician-scientists, clinician-investigators, and laboratory-based scientists who wish to dedicate their career and research efforts to leukemia translational research. To achieve this goal, the CEP will pursue the following specific aims: 1. Recruit, train, and mentor physicians, scientists, and senior postdoctoral fellows to become excellent leukemia investigators focused on leukemia translational research. 2. Educate awardees in all the basic principles of cancer and leukemia biology, including molecular, cellular and systems biology, drug development, pharmacokinetic and pharmacodynamics studies, and basic principles of biostatistics and bioinformatics. 3. Provide a firm foundation for awardees in the specific area of leukemia translational and early clinical research. These objectives will be achieved through strong mentorship in which awardees will be instructed in the principles of clinical, basic, and translational leukemia research. Specific areas of education will include scientific and clinical methods, biomedical ethics, statistical design and analysis, bioinformatics, biology, biochemistry, genetics, epidemiology, and other areas relevant to individual projects. Mentorship will include laboratory-based investigators, clinical-translational investigators, biostatisticians, bioinformaticians and epidemiologists. Mentors from within the Leukemia SPORE and the other 1,500 faculty members at the MD Anderson Cancer Center, Graduate School of Biomedical Sciences, Fox Chase Cancer Center and from the University of Texas in Houston, will provide the expertise required for the development of strong, productive translational research skills. Since its inception in 2003, the CEP has funded 54 awards given to 36 recipients, including 14 women and 14 minorities, who have gained skills and expertise in designing and conducting clinical translational-based studies in leukemia, including incorporating laboratory-based studies in clinical trials and, conversely, transforming critical clinical observations into meaningful laboratory investigations. The majority have continued independent academic careers in leukemia or cancer research. Thus, this program has contributed to the career development of talented young leukemia investigators to hasten the development of effective new therapeutic strategies against leukemia.

Public Health Relevance

(Career Enhancement Program) The Career Enhancement Program fosters the scientific development of investigators who intend to focus their careers on translational studies of leukemia. This is achieved by recruiting innovative entry-level scientists to enhance the SPORE?s overall translational research capability, helping these individuals develop intellectual and technical skills required to be productive investigators, and teaching these individuals basic principles of translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-18
Application #
10006819
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2003-08-05
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Kelly, Andrew D; Madzo, Jozef; Madireddi, Priyanka et al. (2018) Demethylator phenotypes in acute myeloid leukemia. Leukemia 32:2178-2188
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Masarova, Lucia; Verstovsek, Srdan; Hidalgo-Lopez, Juliana E et al. (2018) A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132:1664-1674
Good, Charly Ryan; Panjarian, Shoghag; Kelly, Andrew D et al. (2018) TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. Cancer Res 78:4126-4137
Choi, Sangbum; Kang, Sangwook; Huang, Xuelin (2018) Smoothed quantile regression analysis of competing risks. Biom J 60:934-946
Boddu, Prajwal; Kantarjian, Hagop; Garcia-Manero, Guillermo et al. (2018) The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59:790-802
Yang, Tian-Hui; St John, Lisa S; Garber, Haven R et al. (2018) Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201:1389-1399
Rivera-Del Valle, Nilsa; Cheng, Tiewei; Irwin, Mary E et al. (2018) Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81:483-495
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :

Showing the most recent 10 out of 487 publications